1. A transdermal drug delivery system comprising a layer containing a drug and determining an active surface area and including a polymer matrix containing 0.1 to 10% estradiol based on the total dry weight of said polymer matrix, said system containing more than 0.156 mg / cmstradiol. 2. A transdermal drug delivery system according to claim 1, characterized in that said polymer matrix comprises a polymer mixture comprising an acrylic adhesive, silicone adhesive and soluble polyvinylpyrrolidone (PVP). 3. The transdermal drug delivery system according to claim 1, characterized in that said polymer matrix comprises about 2-25% by weight of acrylic adhesive, about 45-70% by weight of silicone adhesive, about 2-25% by weight of soluble PVP, about 5 -15% penetration enhancer and about 0.1-10% by weight of estradiol, all of which are based on the total dry weight of the polymer matrix. 4. A transdermal drug delivery system according to claim 3, characterized in that said penetration promoting substance comprises oleyl alcohol. Transdermal drug delivery system according to claim 3, characterized in that said penetration promoting substance includes dipropylene glycol. 6. Transdermal drug delivery system according to claim 3, characterized in that said penetration promoting substance comprises oleyl alcohol and dipropylene glycol. 7. Transdermal drug delivery system according to claim 2 or claim 3, characterized in1. Трансдермальная система доставки лекарственного вещества, включающая слой, содержащий лекарственное вещество и определяющий площадь активной поверхности, и включающий полимерную матрицу, содержащую от 0,1 до 10% эстрадиола в расчете на общую сухую массу указанной полимерной матрицы, причем указанная система содержит более 0.156 мг/смэстрадиола.2. Трансдермальная система доставки лекарственного вещества по п. 1, отличающаяся тем, что указанная полимерная матрица включает смесь полимеров, включающую акриловый адгезив, силиконовый адгезив и растворимый поливинилпи
